Delivery Order SPE2DB20D1100-SPE2DB25FE1B1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Linzess 145 microgram capsules (30-count units) valued at $9,140.32. This is a firm fixed-price, competitive delivery order with no set-aside designation and an ultimate completion date of September 15, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This...
- The Defense Logistics Agency awarded a $11,335.78 delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Linzess 290 microgram capsules in quantities of 30 units. This firm fixed-price contract represents a competitively awarded, non-set-aside procurement with a completion date of August 19, 2025. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.80 to AmerisourceBergen Drug Corp for Linzess 72 microgram capsules (30-count units) on September 3, 2025, with an ultimate completion date of September 4, 2025. This competitive award, which carries no set-aside designation, represents a firm fixed-price delivery order for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Linzess 72 mg capsules in a 30-count unit pack, with a contract ceiling value of $1,495.59 and an ultimate completion date of July 21, 2025. This firm fixed price delivery order represents a non-competitive award and is classified as a child contract under AmerisourceBergen's larger federal contracting framework. The performance location is the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $8,164.40 to AmerisourceBergen Drug Corp for Linzess 290 microgram capsules (30-count units) on September 19, 2025, with completion scheduled for September 22, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's broader pharmaceutical supply...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 145 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,676.80. This firm fixed-price delivery order, which is not set-aside for any designated small business category, is scheduled for completion by August 11, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,321.41 to AmerisourceBergen Drug Corp for the supply of Linzess 290 micrograms capsules (30-count units). This competitively awarded, firm fixed-price delivery order was executed on August 20, 2025, with an ultimate completion date of August 21, 2025. The contract represents a small-value pharmaceutical supply transaction fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Linzess 145 mcg capsules (30-count) valued at $3,916.71. This non-competitive delivery order, which is firm fixed price in nature, represents a routine pharmaceutical procurement under the company's broader federal supply agreements. The order is set to be completed by August 13, 2025, with fulfillment occurring at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Linzess 145 micrograms capsules (30-unit package) with a contract value of $14,880.58. This firm fixed price delivery order, which is expected to be completed by August 21, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026). The award was...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE1B1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Linzess 290 microgram capsules (30-count units) at a ceiling value of $1,548.94. This is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The order is scheduled for ultimate completion by August 18, 2025, with performance taking place at the vendor's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors, serves as a critical vendor in the federal medical supply chain, particularly supporting military and veteran healthcare systems. The company maintains extensive delivery order activity across the DLA Medical Supply Chain for a diverse portfolio of pharmaceutical products ranging from specialty medications to vaccines and medical supplies. This Linzess order represents a typical transaction within AmerisourceBergen's broad federal procurement portfolio, demonstrating the company's role as a primary supplier of gastrointestinal medications and other therapeutic agents to defense healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 8/15/25 |